Cambridge, UK, June 15, 2020 — Mundipharma announced today that Marc Princen has joined the Mundipharma network of independently associated companies as the Global Chief Executive Officer, effective June 1, 2020. In his new role, Princen will be responsible for all Mundipharma strategic and operational matters globally, focusing on seamless execution of the 2020-2023 Business Plan.
Speaking of the appointment, Jacques Theurillat, Chairman, said “Marc is a highly proven pharmaceutical executive with a strong track record at leading pharma companies such as Schering-Plough, Merck & Co, Takeda and Allergan. He is widely recognised for his expertise in business change and transformation and joins us at an important moment as we continue our evolution as an organization. I wish him every success in his role with us.”
Marc is joining Mundipharma from Allergan International, where he was the President and EVP, International Business. He brings more than 30 years cross-functional experience in the pharmaceutical Industry with expertise spanning commercial, marketing, business development and management. Marc holds a Bachelor in Physiotherapy degree from Katholieke Universiteit in Leuven, Belgium.
“I am proud and delighted to be joining Mundipharma at this pivotal time,” Princen said. “I see a genuine opportunity to help build a new and exciting future for the organisation as it continues on its transformation journey.”
Notes to editors:
About the Mundipharma network
Mundipharma is a global (ex-US) network of privately-owned independent associated companies with a presence across Africa, Asia Pacific, Europe, Canada, Latin America and the Middle East.
We are dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as Anti-Infectives, Biosimilars, CNS, Diabetes, Oncology & supportive care, Ophthalmology, Pain Management, Respiratory and Consumer Healthcare.
For further information by geographic region please go to www.mundipharma.com (Europe); www.purdue.ca (Canada) and www.mundipharma.com.sg (other ex-US markets).
For further information please contact:
T: +44 (0) 23 81 247 327
T: +44 (0) 7773 009578
Mundipharma has donated supplies of its BETADINE® range of products to hospitals in the Philippines, Thailand and Vietnam to support the efforts of healthcare professionals amidst the outbreak.
The BETADINE® antiseptic range of products contain Povidone-Iodine as the active ingredient. Past laboratory studies indicate that Povidone-Iodine is highly effective against a wide range of viruses such as those which cause SARS and MERS. Povidone-Iodine has also demonstrated broad virucidal efficacy against Ebola virus, Norovirus and influenza virus in several in-vitro studies. Mundipharma is currently evaluating every possibility to test the efficacy of Povidone-Iodine against the novel coronavirus causing the COVID-19 disease.
The BETADINE® antiseptic range of products containing Povidone-Iodine has been trusted by hospitals around the world for over 60 years to prevent and treat infections.
“The escalating severity of the COVID-19 and the dynamically changing conditions are presenting the world with new challenges”, said Mundipharma CEO, Raman Singh.
“Our thoughts and hearts go out to those who are affected by this outbreak and we are grateful to the many healthcare workers and all who are on the front line working tirelessly to contain this virus so that we can be safe and resume our normal daily lives as soon as possible.”
“The donation of BETADINE® products is wholly consistent with our mission and commitment to improving the health and quality of life of the human race everywhere, even in the most extreme circumstances such as these and emphasizes our focus on caring for those most in need,” he added.
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high-quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
Press return to search